A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of KB707 in Subjects with Locally Advanced or Metastatic Solid Tumor Malignancies

Clinical Trial Details

This clinical trial is for men and women with locally advanced or metastatic solid tumor malignancies who have progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy.

The purpose of this study is to evaluate the safety and effectiveness of KB707. KB707 is experimental, which means that it is being tested and is not yet approved by the United States Food and Drug Administration (FDA).

In this study, all participants will receive intratumoral injections of KB707 into measurable, injectable lesions. The study team will discuss the injections and doses with each participant.

Participation is expected to last up to 3 years.

Key Eligibility:

Open to men and women above the age of 18 who have been diagnosed with locally advanced or metastatic solid tumor and the individual has progressed on standard of care therapy.
Participants must not have received prior oncology therapy (chemotherapy, immunotherapy, biological therapy) or use of an investigational agent or an investigational device within 21 days of first dose of KB707

Detailed eligibility will be reviewed when you contact the study team.

Return to List

Study contact by location

Upper East Side - Manhattan

Contact(s)

Alexa Charney, NP
646) 962-6444
anc4034@med.cornell.edu

Primary Investigator(s)

Anna C. Pavlick, DO

Protocol ID(s)

Weill Cornell Medicine IRB #:

2307026280

ClinicalTrials.gov:

NCT05970497

Status

Open to Enrollment

Age Group

Adult

Disease

Cancer

Advanced Solid Tumor

Solid Tumors